Reuters logo
BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck
2017年10月16日 / 下午2点47分 / 1 个月前

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck’s Keytruda® (pembrolizumab) for the treatment of small cell lung cancer

* Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​

* Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​

* Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below